Clinical trials: Acromegaly
Acromegaly Due to Pituitary Adenoma, Hyperglycemia
Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic Diet
Rationale: Pasireotide is a second line medical treatment for acromegaly that can add value for patients with insufficient control of disease on 1st generation SRL, or 1st generation SRL + pegvisomant.
- Conditions
- Acromegaly Due to Pituitary Adenoma, Hyperglycemia, Ketogenic Diet, Standard Care Control
- Trial name
- PasiAcroKeto (NCT07866846)
- Testing
- Ketogenic diet, Diabetes Medication
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Leiden University Medical Center
Acromegaly
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
This study evaluated the safety and efficacy of an increased frequency of octreotide acetate injections or an increase in dose in partially responsive acromegalic patients with persistently uncontrolled disease.
- Trial name
- NCT00372697
- Testing
- Octreotide acetate 30 mg suspension
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
The aim of the study is to compare the risk of acromegaly patients developing valvular regurgitation when receiving lanreotide or octreotide
- Trial name
- NCT00234520
- Where
- 33 sites in Belgium, Czechia and 8 more
- Volunteers
- 225 people
- Sponsor
- Ipsen
Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (also known as CRN00808; an orally administered nonpeptide somatostatin agonist) in subjects with acromegaly previously treated…
- Trial name
- PATHFNDR-1 (NCT04837040)
- Testing
- Paltusotine
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 58 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are responders to…
- Trial name
- NCT03792555
- Testing
- Paltusotine
- Where
- 11 sites in United States, Brazil and 6 more
- Volunteers
- 13 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly
Ultrasound Guided Octreotide LAR Injection in Acromegaly
Approximately half of patients with acromegaly do not respond to treatment with somatostatin receptor ligands such as octreotide LAR.
- Trial name
- NCT00552071
- Testing
- Octreotide LAR 30 MG Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Cedars-Sinai Medical Center
Quality of Life, Acromegaly
Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
Study Synopsis Study Title: Double blind, single centre, cross-over study on the effects of weekly subcutaneous administration of 40 mg pegvisomant or placebo on quality of life and insulin sensitivity in acromegalic patients…
- Trial name
- mec-2005-290 (NCT00642720)
- Testing
- Pegvisomant
- Volunteers
- 20 people
- Sponsor
- Erasmus Medical Center
Acromegaly
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly.
- Trial name
- NCT00225979
- Testing
- Octreotide LAR
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Non Interventional Study For Patients Treated With Somavert®
This open-label, national, prospective, observational, non-interventional, multi-center, post marketing surveillance study was performed in order to examine the efficacy and safety of Somavert® in treatment of subjects with…
- Trial name
- GPOS (NCT00858143)
- Testing
- Non Interventional Observation
- Volunteers
- 311 people
- Sponsor
- Pfizer
Acromegaly
Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China
The purpose of the protocol is to achieve an in-depth understanding of the current satisfaction status of somatostatin analogue (SSA) treatment for acromegaly through patient and physician surveys.
- Trial name
- NCT05184231
- Sponsor
- Ipsen
Acromegaly
Predictive Factors Study
This is a long term study to evaluate common therapeutic algorithms and possible predictive parameters for Somatuline Autogel treatment in patients with Acromegaly.
- Trial name
- TAPAS (NCT02020499)
- Testing
- Somatuline Autogel® (lanreotide) 60, 90, 120 mg.
- Where
- 6 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Ipsen
Acromegaly
Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients
The diagnosis and the follow-up of acromegalic patients are based on the mesurement of Growth hormone (GH) and IGF1 rates. However, the literature described some cases of patient for whom the investigators observed a discrepancy…
- Trial name
- NCT04860037
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Adrenal Insufficiency, Congenital Adrenal Hyperplasia
Dynamic Hormone Diagnostics in Endocrine Disease
The study will investigate 27 hour profiles of hormones in the subcutaneous tissue of healthy subjects and patients with Addison's, Congenital Adrenal Hyperplasia, Growth Hormone Deficiency, acromegaly, Cushings and Primary…
- Conditions
- Adrenal Insufficiency, Congenital Adrenal Hyperplasia, Cushing Syndrome, Growth Hormone Deficiency
- Trial name
- ultradian (NCT02934399)
- Testing
- 27 hour subcutaneous fluid sampling
- Where
- 4 sites in Greece, Norway and 2 more
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Acromegaly
Late Effects of Radiosurgery on Acromegaly Study
Transsphenoidal surgery is the first-line treatment of acromegaly. Adjunctive radiotherapy can be necessary when surgery is ineffective to avoid a prolonged medical treatment.
- Trial name
- LateRAc (NCT02296216)
- Testing
- Gamma Knife radiosurgery
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Acromegaly
One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
This non-interventional retrospective study aims to describe the therapeutic procedures and modalities received by patients and the correlation to hormone status, during a one year follow up from completion of the 2-79-52030-207…
- Trial name
- NCT01471405
- Where
- 18 sites in Czechia, France and 4 more
- Volunteers
- 54 people
- Sponsor
- Ipsen
Acromegaly
Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control.
- Trial name
- STOP-SST (NCT05149495)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Acromegaly Due to Pituitary Adenoma
Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor
Modulation of the GIP System in Patients With Acromegaly Due to a Pituitary adenoma
- Trial name
- GA-9 (NCT03807076)
- Testing
- GIP-A
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- University of Copenhagen
Acromegaly
Lanreotide Levels in Acromegaly
Recently lanreotide (a somatostatin analog) has come into the US marketplace as a commercially available medication approved by the FDA for the treatment of acromegaly.
- Trial name
- NCT00916916
- Testing
- Blood draw
- Where
- United States
- Sponsor
- Cedars-Sinai Medical Center
Acromegaly
Study of MAR002 in Healthy Men
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men
- Trial name
- NCT07195175
- Testing
- MAR002
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Marea Therapeutics
Acromegaly
Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the safety profile of C2L-OCT-01 PR for up to an additional 96-week period in acromegalic patients who completed the C2L-OCT-01 PR-301 study.
- Trial name
- NCT00635765
- Testing
- C2L-OCT-01 PR 30 mg
- Where
- 6 sites in Belarus, Hungary and 4 more
- Volunteers
- 63 people
- Sponsor
- Ambrilia Biopharma, Inc.